[Federal Register Volume 88, Number 186 (Wednesday, September 27, 2023)]
[Notices]
[Page 66467]
[FR Doc No: 2023-21026]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA-4726-DR; Docket ID FEMA-2023-0001]

Montana; Amendment No. 1 to Notice of a Major Disaster
Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice amends the notice of a major disaster declaration
for the State of Montana (FEMA-4726-DR), dated August 12, 2023, and
related determinations.

DATES: This change occurred on August 14, 2023.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and
Recovery, Federal Emergency Management Agency, 500 C Street SW,
Washington, DC 20472,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The Federal Emergency Management Agency
(FEMA) hereby gives notice that pursuant to the authority vested in the
Administrator, under Executive Order 12148, as amended, Alana B. Kuhn,
of FEMA is appointed to act as the Federal Coordinating Officer for
this disaster.
    This action terminates the appointment of Jon K. Huss as Federal
Coordinating Officer for this disaster.

    The following Catalog of Federal Domestic Assistance Numbers
(CFDA) are to be used for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis
Counseling; 97.033, Disaster Legal Services; 97.034, Disaster
Unemployment Assistance (DUA); 97.046, Fire Management Assistance
Grant; 97.048, Disaster Housing Assistance to Individuals and
Households In Presidentially Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance--Disaster Housing
Operations for Individuals and Households; 97.050, Presidentially
Declared Disaster Assistance to Individuals and Households--Other
Needs; 97.036, Disaster Grants--Public Assistance (Presidentially
Declared Disasters); 97.039, Hazard Mitigation Grant.

Deanne Criswell,
Administrator, Federal Emergency Management Agency.
[FR Doc. 2023-21026 Filed 9-26-23; 8:45 am]
BILLING CODE 9111-23-P


[Federal Register Volume 77, Number 229 (Wednesday, November 28, 2012)]
[Notices]
[Pages 71006-71008]
[FR Doc No: 2012-28773]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-1134

Sodium Nitrite Injection and Sodium Thiosulfate Injection Drug
Products Labeled for the Treatment of Cyanide Poisoning; Enforcement
Action Dates

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its
intention to take enforcement action against unapproved injectable drug
products containing sodium nitrite labeled for the treatment of cyanide
poisoning and unapproved injectable drug products containing sodium
thiosulfate labeled for the treatment of cyanide poisoning, and persons
who manufacture or cause the manufacture or distribution of such
products in interstate commerce. Cyanide antidotes carry serious risks
and some unapproved drug products may lack Boxed Warnings and other
warnings required in the labeling of approved cyanide antidotes. These
unapproved drug products compete with approved products, and thus pose
a direct challenge to the drug approval system. Injectable drug
products containing sodium nitrite or sodium thiosulfate that are
labeled for the treatment of cyanide poisoning are new drugs that
require approved new drug applications (NDAs) or abbreviated new drug
applications (ANDAs) in order to be legally marketed.

DATES: This notice is effective November 28, 2012. For information
about enforcement dates, see SUPPLEMENTARY INFORMATION, section IV.

ADDRESSES: All communications in response to this notice should be
identified with Docket No. FDA-2012-N-1134 and directed to the
appropriate office listed in this document.
    Applications under section 505(b) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 355(b)): Division of Anesthesia,
Analgesia, and Addiction Products, Office of New Drugs, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Silver Spring, MD 20993-0002.
    Applications under section 505(j) of the FD&C Act (21 U.S.C.
355(j)): Office of Generic Drugs, Center for Drug Evaluation and
Research, Food and Drug Administration, 7519 Standish Pl., Rockville,
MD 20855.
    All other communications: Lori Cantin, Office of Unapproved Drugs
and Labeling Compliance, Division of Prescription Drugs, Center for
Drug Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 5239, Silver Spring, MD 20993-0002.

FOR FURTHER INFORMATION CONTACT: Lori Cantin, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 5239, Silver Spring, MD 20993-0002, 301-
796-1212, email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    Cyanide is highly toxic in humans and can be fatal if not
immediately treated with an effective antidote. On January 14, 2011,
FDA approved NDA 201444 for Nithiodote, a co-packaged Sodium Nitrite
Injection and Sodium Thiosulfate Injection drug product, labeled for
treatment of acute cyanide poisoning that is judged to be life-
threatening. On February 14, 2012, FDA approved NDA 203922 for Sodium
Nitrite Injection for sequential use with sodium thiosulfate for
treatment of acute cyanide poisoning that is judged to be life-
threatening, and NDA 203923 for Sodium Thiosulfate Injection for
sequential use with sodium nitrite for treatment of acute cyanide
poisoning that is judged to be life-threatening. Sodium thiosulfate and
sodium nitrite pose the risk of hypotension (low blood pressure), and
sodium nitrite also poses the risk of methemoglobinemia, a disorder
characterized by the presence of a higher than normal level of
methemoglobin in the blood. Methemoglobin is an oxidized form of
hemoglobin that has a decreased affinity for oxygen, resulting in a
reduced ability to release oxygen to body tissue. Methemoglobinemia can
lead to neurological and cardiac symptoms due to lack of adequate
oxygen in body tissues. The approved Sodium Nitrite Injection and
Nithiodote carry Boxed Warnings for these serious adverse reactions.
    FDA is aware of several unapproved drug products containing sodium
nitrite or sodium thiosulfate labeled to treat cyanide poisoning. These
unapproved drug products containing sodium nitrite or sodium
thiosulfate are sold individually, as well as in cyanide antidote kits.
Unapproved cyanide antidote kits may also contain other unapproved
drugs (e.g., amyl nitrite) or medical products (e.g., syringes) that
are intended for potential use with sodium nitrite and sodium
thiosulfate. This notice is issued under sections 502 (21 U.S.C. 352)
and 505 of the FD&C Act and applies to unapproved injectable drug
products containing sodium nitrite or sodium thiosulfate labeled to
treat cyanide poisoning that are currently being manufactured or
distributed.

II. Safety Concerns With Unapproved New Drugs

    Because marketed unapproved new drug products have not been through
FDA's approval process, there are safety risks associated with them.
Some unapproved drug product labeling omits safety warnings, such as
the Boxed Warnings required on Sodium Nitrite Injection and Nithiodote,
which are important for safe use of the drug products. Without these
warnings, the unapproved drug products may be used in inappropriate
circumstances or without appropriate monitoring, posing an increased
risk to public health. Patients being treated for cyanide poisoning
require close monitoring and may require repeat doses of antidote,
supplemental oxygen, and ventilatory support. Cyanide antidotes
containing sodium nitrite or amyl nitrite may induce methemoglobinemia,
which may require additional treatment.

    The expected risks associated with use of sodium nitrite or sodium
thiosulfate drug products are also potentially greater for unapproved
drug products because the quality, safety, and efficacy of unapproved
formulations have not been demonstrated to FDA. For example,
information on the ingredients and data on the bioavailability of
unapproved drug products have not been submitted for FDA review, nor
has FDA had the opportunity to assess the adequacy of their chemistry,
manufacturing, and control specifications. Also, unapproved drug
products have unapproved labeling that may not contain appropriate
dosing information. For example, the sodium thiosulfate component of
Nithiodote is dosed for children based on body weight or body surface
area, whereas FDA is aware of unapproved sodium thiosulfate products
labeled for use in children at a lower dose based only on body surface
area. Such discrepancies in dosing may lead to underdosing of sodium
thiosulfate in children.

III. Legal Status of Products Identified in This Notice

    FDA has reviewed the publicly available scientific literature for
unapproved injectable sodium nitrite and sodium thiosulfate products
labeled for treatment of cyanide poisoning. In no case did FDA find
literature sufficient to support a determination that any of these drug
products are generally recognized as safe and effective. Therefore,
these products are ``new drugs'' within the meaning of section 201(p)
of the FD&C Act (21 U.S.C. 321(p)), and they require approved NDAs or
ANDAs in order to be legally marketed.
    Also, the unapproved drug products covered by this notice are
labeled for prescription use. Prescription drugs are defined under
section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)) as drugs
that, because of their toxicity or other potentiality for harmful
effect, are not safe to use except under the supervision of a
practitioner licensed by law to administer such drugs. Because any drug
product covered by this notice meets the definition of ``prescription
drug'' in 503(b)(1)(A), adequate directions cannot be written for it so
that a layman can use the product safely for its intended uses (21 CFR
201.5). Consequently, it is misbranded under section 502(f)(1) of the
FD&C Act in that it fails to bear adequate directions for use. An
approved prescription drug is exempt from the requirement in section
502(f)(1) that it bear adequate direction for use if, among other
things, it bears the NDA-approved labeling (21 CFR 201.100(c)(2) and 21
CFR 201.115). Because the unapproved prescription drug products subject
to this notice do not have approved applications with approved
labeling, they fail to qualify for the exemptions to the requirement
that they bear ``adequate directions for use,'' and they are misbranded
under section 502(f)(1).

IV. Notice of Intent To Take Enforcement Action

    Although not required to do so by the Administrative Procedure Act,
the FD&C Act (or any rules issued under its authority), or for any
other legal reason, FDA is providing this notice to persons \1\ who are
marketing unapproved and misbranded drug products containing sodium
nitrite and sodium thiosulfate labeled to treat cyanide poisoning,
either sold individually or as part of a kit. The Agency intends to
take enforcement action against such products and those who manufacture
them or cause them to be manufactured or shipped in interstate
commerce. In the event that unapproved sodium nitrite and sodium
thiosulfate are packaged in a kit with other unapproved drugs (e.g.,
amyl nitrite) or medical products (e.g., syringes) and labeled for
treatment of cyanide poisoning, FDA intends to take action against the
entire kit based on the unapproved sodium thiosulfate and sodium
nitrite components.
---------------------------------------------------------------------------

    \1\ The term person includes individuals, partnerships,
corporations, and associations (21 U.S.C. 321(e)).
---------------------------------------------------------------------------

    Manufacturing or shipping the drug products covered by this notice
can result in enforcement action, including seizure, injunction, or
other judicial or administrative proceeding. Consistent with policies
described in the Agency's guidance entitled ``Marketed Unapproved
Drugs--Compliance Policy Guide'' (the Marketed Unapproved Drugs CPG)
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070290.pdf), the
Agency does not expect to issue a warning letter or any other further
warning to firms marketing drug products covered by this notice before
taking enforcement action. The Agency also reminds firms that, as
stated in the Marketed Unapproved Drugs CPG, any unapproved drug
marketed without a required approved application is subject to Agency
enforcement action at any time. The issuance of this notice does not in
any way obligate the Agency to issue similar notices (or any notice) in
the future regarding marketed unapproved drugs. As described in the
Marketed Unapproved Drugs CPG, the Agency may, at its discretion,
identify a period of time during which the Agency does not intend to
initiate an enforcement action against a currently marketed unapproved
drug solely on the grounds that it lacks an approved application under
section 505 of the FD&C Act. With respect to drug products covered by
this notice, the Agency intends to exercise its enforcement discretion
for only a limited period of time because there are safety risks with
respect to the products covered by this notice, and there are FDA-
approved drug products to meet patient needs. Therefore, the Agency
intends to implement this notice as follows.
    For the effective date of this notice, see the DATES section of
this document. Any drug product covered by this notice that a company
(including a manufacturer or distributor) began marketing after
September 19, 2011, is subject to immediate enforcement action. For
products covered by this notice that a company (including a
manufacturer or distributor) began marketing in the United States on or
before September 19, 2011, FDA intends to take enforcement action
against any such product that is not listed with the Agency in full
compliance with section 510 of the FD&C Act (21 U.S.C. 360) before
November 27, 2012, and is manufactured, shipped, or otherwise
introduced or delivered for introduction into interstate commerce by
any person on or after November 27, 2012. FDA also intends to take
enforcement action against any drug product covered by this notice that
is listed with FDA in full compliance with section 510 of the FD&C Act
but is not being commercially used or sold \2\ in the United States
before November 27, 2012 and that is manufactured, shipped, or
otherwise introduced or delivered for introduction into interstate
commerce by any person on or after November 28, 2012.
---------------------------------------------------------------------------

    \2\ For purposes of this notice, the phrase ``commercially used
or sold'' means that the product has been used in a business or
activity involving retail or wholesale marketing and/or sale.
---------------------------------------------------------------------------

    However, for drug products covered by this notice that a company
(including a manufacturer or distributor) began marketing in the United
States on or before September 19, 2011, are listed with FDA in full
compliance with section 510 of the FD&C Act before November 27, 2012
(``currently marketed and listed''), and are manufactured, shipped, or
otherwise introduced or delivered for introduction into interstate
commerce by any person on or after November 28, 2012 the Agency intends
to exercise its

enforcement discretion as follows: FDA intends to initiate enforcement
action against any such currently marketed and listed product that is
manufactured on or after February 26, 2013, or that is shipped on or
after May 28, 2013. Further, FDA intends to take enforcement action
against any person who manufactures or ships such products after these
dates. Any person who has submitted or submits an application for a
drug product covered by this notice but has not received approval must
comply with this notice.
    The Agency, however, does not intend to exercise its enforcement
discretion as outlined previously if the following apply: (1) A
manufacturer or distributor of drug products covered by this notice is
violating other provisions of the FD&C Act, including, but not limited
to, violations related to FDA's current good manufacturing practice,
adverse event reporting, labeling, or misbranding requirements other
than those identified in this notice, or (2) it appears that a firm, in
response to this notice, increases its manufacture or interstate
shipment of drug products covered by this notice above its usual volume
during these periods.\3\
---------------------------------------------------------------------------

    \3\ If FDA finds it necessary to take enforcement action against
a product covered by this notice, the Agency may take action
relating to all of the defendant's other violations of the FD&C Act
at the same time. For example, if a firm continues to manufacture or
market a product covered by this notice after the applicable
enforcement date has passed, to preserve limited Agency resources,
FDA may take enforcement action relating to all of the firm's
unapproved drugs that require applications at the same time (see,
e.g., United States v. Sage Pharmaceuticals, 210 F.3d 475, 479-480
(5th Cir. 2000) (permitting the Agency to combine all violations of
the FD&C Act in one proceeding, rather than taking action against
multiple violations of the FD&C Act in ``piecemeal fashion'')).
---------------------------------------------------------------------------

    Nothing in this notice, including FDA's intent to exercise its
enforcement discretion, alters any person's liability or obligations in
any other enforcement action, or precludes the Agency from initiating
or proceeding with enforcement action in connection with any other
alleged violation of the FD&C Act, whether or not related to a drug
product covered by this notice. Similarly, a person who is or becomes
enjoined from marketing unapproved or misbranded drugs may not resume
marketing of such products based on FDA's exercise of enforcement
discretion as described in this notice.
    Drug manufacturers and distributors should be aware that the Agency
is exercising its enforcement discretion as described previously only
in regard to drug products covered by this notice that are marketed
under a National Drug Code number listed with the Agency in full
compliance with section 510 of the FD&C Act before November 27, 2012.
As previously stated, drug products covered by this notice that are
currently marketed but not listed with the Agency on the date of this
notice must, as of the effective date of this notice, have approved
applications before their shipment in interstate commerce. Moreover,
any person or firm that has submitted or submits an application but has
yet to receive approval for such products is still responsible for full
compliance with this notice.

V. Discontinued Products

    Some firms may have previously discontinued the manufacturing or
distribution of products covered by this notice without removing them
from the listing of their products under section 510(j) of the FD&C
Act. Other firms may discontinue manufacturing or distributing listed
products in response to this notice. Firms that wish to notify the
Agency of product discontinuation should send a letter, signed by the
firm's chief executive officer, fully identifying the discontinued
product(s), including NDC number(s), and stating that the manufacturing
and/or distribution of the products has (have) been discontinued. The
letter should be sent electronically to Lori Cantin (see ADDRESSES).
Firms should also electronically update the listing of their products
under section 510(j) of the FD&C Act to reflect discontinuation of
products covered by this notice. Questions on electronic drug listing
updates should be sent to<EMAIL_ADDRESS>FDA plans to rely on its
existing records, including its drug listing records, the results of
any subsequent inspections, or other available information, when it
targets violations for enforcement action.

    Dated: November 20, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-28773 Filed 11-27-12; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 87, Number 134 (Thursday, July 14, 2022)]
[Notices]
[Pages 42235-42236]
[FR Doc No: 2022-14979]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 34644; File No. 812-15090]

Sixth Street Specialty Lending, Inc., et al

July 8, 2022.
AGENCY: Securities and Exchange Commission (``Commission'' or ``SEC'').

ACTION: Notice.

-----------------------------------------------------------------------

    Notice of application for an order (``Order'') under sections 17(d)
and 57(i) of the Investment Company Act of 1940 (the ``Act'') and rule
17d-1 under the Act to permit certain joint transactions otherwise
prohibited by sections 17(d) and 57(a)(4) of the Act and rule 17d-1
under the Act.

Summary of Application: Applicants request an order to permit certain
business development companies (``BDCs'') and closed-end management
investment companies to co-invest in portfolio companies with each
other and with certain affiliated investment entities.

Applicants: Sixth Street Specialty Lending, Inc., Sixth Street
Specialty Lending Advisers, LLC, Sixth Street Opportunities Partners
III (A), L.P., Sixth Street Opportunities Partners III (B), L.P., Sixth
Street Opportunities Partners III (C), L.P., TOP III Delaware AIV I-A,
L.P., Opps III Delaware AIV I-B, L.P., Sixth Street Opportunities
Partners IV (A), L.P., Sixth Street Opportunities Partners IV (B),
L.P., Sixth Street Opportunities Partners IV (C), L.P., Opps IV
Delaware AIV I-A, L.P., Opps IV Delaware AIV I-B, L.P., Sixth Street
Opportunities Partners V (A), L.P., Sixth Street Opportunities Partners
V (B), L.P., Sixth Street Opportunities Partners V (C), L.P., Sixth
Street Opps V Delaware AIV I-A, L.P., Sixth Street Opps V Delaware AIV
I-B, L.P., Sixth Street TAO Partners, L.P., Sixth Street TAO Partners
(A), L.P., Sixth Street TAO Partners (B), L.P., Sixth Street TAO
Partners (C), L.P., Sixth Street TAO Partners (D), L.P., Sixth Street
TAO Partners (E), L.P., Sixth Street TAO Partners (F), L.P., Super TAO
Contingent MA, L.P., Knight TAO, L.P., Super TAO MA, L.P., PSERS TAO
Partners Parallel Fund, L.P., TAO (B) AIV II-A, L.P., TAO (C) AIV II-A,
L.P., TAO (D) AIV II-A, L.P., TAO (E) AIV II-A, L.P., Sixth Street
Growth Partners (A), L.P., Sixth Street Growth Partners (B), L.P.,
Sixth Street Growth Partners (A) AIV, L.P., Sixth Street Growth
Partners (B) AIV, L.P., Sixth Street Growth Partners II (A), L.P.,
Sixth Street Growth Partners II (B), L.P., Sixth Street Growth II (A)
AIV, L.P., Sixth Street Growth II (B) AIV, L.P., Growth II Lending,
LLC, Sixth Street Fundamental Strategies Partners (A), L.P., Sixth
Street Fundamental Strategies Partners (B), L.P., Sixth Street FS AIV
I-A, L.P., Sixth Street FS AIV I-B, L.P., Sixth Street Specialty
Lending Europe I, L.P., Sixth Street Specialty Lending Europe II, L.P.,
Super TSLE, L.P., Sixth Street Agriculture Partners (A), L.P., Sixth
Street Bluegrass Strategic Holdings I, L.P., Sixth Street Willow
Strategic Holdings I, L.P., Sixth Street Cottonwood Strategic Holdings
I, L.P., Sixth Street Dogwood Strategic Holdings I, L.P., Sixth Street
Red Pine Strategic Holdings I, L.P., Sixth Street CMS Dynamic Credit
Fund, L.P., TCS Lending, LLC, TDL Lending, LLC, TOP IV Lending, LLC,
Opps V Lending, LLC, FS I Lending, LLC, TICP CLO V 2016-1, Ltd., TICP
CLO VI 2016-2, Ltd., TICP CLO VII, Ltd., TICP CLO VIII, Ltd., TICP

CLO IX, Ltd., TICP CLO X, Ltd., TICP CLO XI, Ltd., TICP CLO XII, Ltd.,
TICP CLO XIII, Ltd., TICP CLO XIV, Ltd., TICP CLO XV, Ltd., Sixth
Street CLO XVI, Ltd., Sixth Street CLO XVII, Ltd., Sixth Street CLO
XVIII, Ltd., Sixth Street CLO XIX, Ltd., Sixth Street CLO XX, Ltd.,
Sixth Street CLO Equity Fund IV, L.P., TSSP Rotational Credit Fund,
L.P., Sixth Street Wheeler Peak Rotational Credit Fund I, LLC, Sixth
Street Rotational Credit Fund III, L.P., TSSP Structured Credit
Opportunities Fund, L.P., Sixth Street Structured Credit Opportunities
Fund II, L.P., Sixth Street Structured Credit Opportunities Fund III,
L.P., Sixth Street Structured Credit Opportunities Fund IV, L.P., Sixth
Street Structured Credit Opportunities Fund V, L.P., TICP CLO Partners
II, L.P., TICP CLO Holdings, L.P., TSSP Institutional Credit Partners
III, L.P., Sixth Street Credit Market Strategies Partners I, L.P.,
Sixth Street Credit Market Strategies Partners I-A, L.P., TICP III
Cayman, Ltd., Sixth Street Mid-Stage Growth Partners (A), L.P., Sixth
Street Mid-Stage Growth Partners (B), L.P., Sixth Street Mid-Stage
Growth (A) AIV, L.P., Sixth Street Mid-Stage Growth (B) AIV, L.P.,
Sixth Street Advisers, LLC, Sixth Street Fundamental Strategies I
Management, LLC, Sixth Street Opportunities III Management, LLC, Sixth
Street Opportunities IV Management, LLC, Sixth Street Opportunities V
Management, LLC, Sixth Street TAO Management, LLC, Sixth Street Growth
I Management, LLC, Sixth Street Growth II Management, LLC, Sixth Street
Specialty Lending Europe I Management, LLC, Sixth Street Specialty
Lending Europe II Management, LLC, Sixth Street Agriculture Management,
LLC, Sixth Street Strategic Holdings Management, LLC, Sixth Street CMS
Dynamic Credit Management, LLC, TICP CLO V 2016-1 Management, LLC, TICP
CLO VI 2016-2 Management, LLC, TICP CLO VII Management, LLC, TICP CLO
VIII Management, LLC, TICP CLO IX Management, LLC, TICP CLO X
Management, LLC, TICP CLO XI Management, LLC, TICP CLO XII Management,
LLC, TICP CLO XIII Management, LLC, TICP CLO XIV Management, LLC, TICP
CLO XV Management, LLC, Sixth Street CLO XVI Management, LLC, Sixth
Street CLO XVII Management, LLC, Sixth Street CLO XVIII Management,
LLC, Sixth Street CLO XIX Management, LLC, Sixth Street CLO XX
Management, LLC, Sixth Street CLO Equity IV Management, LLC, TSSP
Rotational Credit Management, LLC, Sixth Street Rotational Credit II
Management, LLC, Sixth Street Rotational Credit III Management, LLC,
TSSP Structured Credit Opportunities Management, LLC, Sixth Street
Structured Credit Opportunities II Management, LLC, Sixth Street
Structured Credit Opportunities III Management, LLC, Sixth Street
Structured Credit Opportunities IV Management, LLC, Sixth Street
Structured Credit Opportunities V Management, LLC, Sixth Street CLO
Advisers II, LLC, TSSP Institutional Credit III Management, LLC, Sixth
Street Credit Market Strategies Management, LLC, Sixth Street Mid-Stage
Growth I Management, LLC, MSGP Lending, LLC, Sixth Street Lending
Partners Advisers, LLC and Sixth Street Lending Partners.

Filing Dates: The application was filed on January 16, 2020, and
amended on July 20, 2021, December 28, 2021, May 26, 2022, and June 29,
2022.

Hearing or Notification of Hearing: An order granting the requested
relief will be issued unless the Commission orders a hearing.
Interested persons may request a hearing on any application by emailing
the SEC's Secretary at [email protected] and serving the
Applicants with a copy of the request by email, if an email address is
listed for the relevant Applicant below, or personally or by mail, if a
physical address is listed for the relevant Applicant below. Hearing
requests should be received by the Commission by 5:30 p.m. on August 2,
2022, and should be accompanied by proof of service on applicants, in
the form of an affidavit or, for lawyers, a certificate of service.
Pursuant to rule 0-5 under the Act, hearing requests should state the
nature of the writer's interest, any facts bearing upon the
desirability of a hearing on the matter, the reason for the request,
and the issues contested. Persons who wish to be notified of a hearing
may request notification by emailing the Commission's Secretary at
[email protected].

ADDRESSES: The Commission: [email protected]. Applicants:
Joshua Peck, [email protected]; John J. Mahon, Esq.,
[email protected].

FOR FURTHER INFORMATION CONTACT: Jennifer O. Palmer, Senior Counsel, or
Terri G. Jordan, Branch Chief, at<PHONE_NUMBER> (Division of
Investment Management, Chief Counsel's Office).

SUPPLEMENTARY INFORMATION: For Applicants' representations, legal
analysis, and conditions, please refer to Applicants' fourth amended
and restated application, dated June 29, 2022, which may be obtained
via the Commission's website by searching for the file number at the
top of this document, or for an Applicant using the Company name search
field, on the SEC's EDGAR system. The SEC's EDGAR system may be
searched at, at http://www.sec.gov/edgar/searchedgar/legacy/companysearch.html. You may also call the SEC's Public Reference Room
at<PHONE_NUMBER>.

    For the Commission, by the Division of Investment Management,
under delegated authority.
J. Matthew DeLesDernier,
Assistant Secretary.
[FR Doc. 2022-14979 Filed 7-13-22; 8:45 am]
BILLING CODE 8011-01-P